MustGrow Biologics Reports Revenue Increase Driven by TerraSante US Sales

MustGrow Biologics reported a significant revenue increase in 2025, driven by strong sales of its TerraSante biofertility product in the US. Revenue rose to $8.3 million from $0.4 million in 2024, though the company experienced a wider net loss due to increased operating expenses.

By Proactive Thu, April 30, 2026 at 3:38 PM GMT+3 2 min read · Yahoo Finance · April 30, 2026, 12:38 UTC

MustGrow Biologics Reports Revenue Increase Driven by TerraSante US Sales

Topics: biological agriculture financial results revenue growth sales increase TerraSante

Read the full article at Yahoo Finance

More World news

Blackbaud Reports Third Quarter Revenue Growth and Strategic AI Integration Motley Fool · November 12, 2026, 17:53 UTC
Sprott Physical Copper Trust Reports Significant Increase in Q3 Net Income Seeking Alpha · November 12, 2026, 17:51 UTC
Federal Reserve to Designate October 2027 Meeting as Non-Voting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC